BRAF突变晚期结直肠癌:快速变化的治疗格局
本文综述BRAF突变晚期结直肠癌的功能分类及治疗进展。BRAF突变按信号机制分三类,其中I类BRAFV600E突变在结直肠癌中最常见。基于近期临床试验,BRAFV600E突变转移性结直肠癌的当前标准治疗包括一线细胞毒化疗联合贝伐珠单抗,后续使用BRAF抑制剂恩科拉非尼联合抗表皮生长因子受体抗体西妥昔单抗。
要点
- BRAF突变按信号机制分三类,I类BRAFV600E在结直肠癌中最常见。
- BRAFV600E突变转移性结直肠癌一线标准为化疗联合贝伐珠单抗。
- 后续标准治疗为恩科拉非尼联合西妥昔单抗。
核心结论
- BRAF突变晚期结直肠癌的治疗格局正在快速变化,基于近期临床试验已形成当前标准治疗。
研究设计与样本
- 本文为综述,基于近期临床试验总结BRAF突变晚期结直肠癌的治疗进展。
主要发现
- BRAF突变按信号机制分为三个功能类别,I类BRAFV600E突变在结直肠癌中发生最频繁。
- BRAF突变的功能分类显示不同的丝裂原活化蛋白激酶通路信号传导。
- BRAFV600E突变转移性结直肠癌的当前标准治疗包括一线细胞毒化疗联合贝伐珠单抗,以及后续BRAF抑制剂恩科拉非尼联合抗表皮生长因子受体抗体西妥昔单抗。
- 正在探索的治疗方案包括多种通路靶向治疗、细胞毒化疗和/或免疫检查点阻断的联合方案。
- 规避BRAF靶向治疗的适应性和获得性耐药是BRAF突变晚期结直肠癌需要克服的重大挑战。
关键数值与推荐
- BRAF突变按信号机制分为三个功能类别,I类BRAFV600E突变在结直肠癌中最常见。
- BRAFV600E突变转移性结直肠癌当前标准治疗:一线细胞毒化疗联合贝伐珠单抗;后续恩科拉非尼联合西妥昔单抗。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BRAF-mutated advanced colorectal cancer is a relatively small but critical subset of this tumor type on the basis of prognostic and predictive implications. BRAF alterations in colorectal cancer are classified into three functional categories on the basis of signaling mechanisms, with the class I BRAFV600E mutation occurring most frequently in colorectal cancer. Functional categorization of BRAF mutations in colorectal cancer demonstrates distinct mitogen-activated protein kinase pathway signaling. On the basis of recent clinical trials, current standard-of-care therapies for patients with BRAFV600E-mutated metastatic colorectal cancer include first-line cytotoxic chemotherapy plus bevacizumab and subsequent therapy with the BRAF inhibitor encorafenib and antiepidermal growth factor receptor antibody cetuximab. Treatment regimens currently under exploration in BRAFV600E-mutant metastatic colorectal cancer include combinatorial options of various pathway-targeted therapies, cytotoxic chemotherapy, and/or immune checkpoint blockade, among others. Circumvention of adaptive and acquired resistance to BRAF-targeted therapies is a significant challenge to be overcome in BRAF-mutated advanced colorectal cancer.
引用
- Ciombor KK, Strickler JH, Bekaii-Saab TS, et al. BRAF-Mutated Advanced Colorectal Cancer: A Rapidly Changing Therapeutic Landscape. J Clin Oncol. 2022. PMID: 35649231. doi:10.1200/JCO.21.02541
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。